原发性开角型青光眼(POAG)是一种不可逆性致盲眼病,严重威胁和损害视神经及其视觉通路。因POAG发病原因及影响因素的多样化,探讨其发病机制一直是该领域研究的热点。但目前尚缺乏对POAG病因、疗效及预后进行精准判定和可量化的生物学标志物。近些年,代谢组学作为一门新兴的检测方法,在眼科主要用于疾病的预测、诊断和预后评估过程,为临床提供具有指导意义的特征性代谢物。POAG是代谢组学技术应用较早的眼科疾病之一,研究者们利用非靶向、靶向和广泛靶向等代谢组学方法,依靠核磁共振谱和质谱技术平台,筛选出众多具有高度选择性、灵敏性、特异性的生物代谢物产物和生物标志物,并建立起代谢组学在POAG应用研究中用于追踪生物体各水平发生变化的系统和技术平台,为今后代谢组学在POAG临床研究中的进一步应用奠定基础。本文就代谢组学及其临床研究意义、基于动物模型的代谢组学研究进展和POAG患者临床代谢组学研究进展进行综述。
Primary open-angle glaucoma (POAG) is an irreversible blinding eye disease that severely threatens and damages the optic nerve and visual pathways.Due to the diversity of causes and factors influencing its pathogenesis, the study of its pathogenesis has been a hot spot for research in this field.In recent years, metabolomics, as an emerging method, has been mainly applied in the prediction, diagnosis and prognosis assessment of ophthalmic diseases, providing characteristic metabolites with clinical guidance.Untargeted, targeted and widely targeted metabolomics methods based on nuclear magnetic resonance spectroscopy and mass spectrometry platforms have been applied to screen a large number of highly selective, sensitive and specific biometabolite products and biomarkers, and systems and technical platforms for metabolomics have been developed to track biological changes at all levels in POAG research, providing a foundation for further application of metabolomics in POAG clinical research in the future.This article reviews metabolomics and its clinical implications, advances in animal model-based metabolomics research, and advances in clinical metabolomics research in patients with POAG.
许健明,张铭志. 代谢组学在原发性开角型青光眼中的研究进展及前景[J]. 中华实验眼科杂志,2023,41(12):1221-1226.
DOI:10.3760/cma.j.cn115989-20220518-00224版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章,不得使用本刊的版式设计。
除非特别声明,本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。